Search Results - "O'Doherty, Catherine"

Folate and methionine metabolism in autism: a systematic review [Erratum: 2010 Oct., v, 92, no 4, p. 1001] by Main, Penelope AE, Angley, Manya T, Thomas, Philip, O'Doherty, Catherine E, Fenech, Michael

“…BACKGROUND: Autism is a complex neurodevelopmental disorder that is increasingly being recognized as a public health issue. Recent evidence has emerged that…”
Get full text

The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis by Main, Penelope Ae, Angley, Manya T, O'Doherty, Catherine E, Thomas, Philip, Fenech, Michael

“…Glutathione has a wide range of functions; it is an endogenous anti-oxidant and plays a key role in the maintenance of intracellular redox balance and…”
Get full text

Putting recommendations into practice: Australian rheumatologists’ opinions on leflunomide use in rheumatoid arthritis by Hopkins, Ashley M., Wiese, Michael D., O’Doherty, Catherine E., Proudman, Susanna M.

“…Leflunomide is the most recently introduced conventional disease-modifying anti-rheumatic drugs in Australia. It has several unique methods for initiation,…”
Get full text

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis by Hopkins, Ashley M., Wiese, Michael D., Proudman, Susanna M., O'Doherty, Catherine E., Upton, Richard N., Foster, David J. R.

“…Aim Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) treatment, yet approximately 20 to 40% of patients cease due to…”
Get full text

Prevalence and Characteristics of Breakthrough Pain in Cancer Patients Admitted to a Hospice by Zeppetella, Giovambattista, O'Doherty, Catherine A, Collins, Silke

“…A prospective survey was undertaken to determine the prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. Of 414…”
Get full text

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide by Hopkins, Ashley M., Vitry, Agnes I., O'Doherty, Catherine E., Proudman, Susanna M., Wiese, Michael D.

Get full text

Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study by Nicholson, Brian D, Oke, Jason, Virdee, Pradeep S, Harris, Dean A, O'Doherty, Catherine, Park, John ES, Hamady, Zaed, Sehgal, Vinay, Millar, Andrew, Medley, Louise, Tonner, Sharon, Vargova, Monika, Engonidou, Lazarina, Riahi, Kaveh, Luan, Ying, Hiom, Sara, Kumar, Harpal, Nandani, Harit, Kurtzman, Kathryn N, Yu, Ly-Mee, Freestone, Clare, Pearson, Sarah, Hobbs, FD Richard, Perera, Rafael, Middleton, Mark R

“…Analysis of circulating tumour DNA could stratify cancer risk in symptomatic patients. We aimed to evaluate the performance of a methylation-based multicancer…”
Get full text

Identification of shared genes and pathways: a comparative study of multiple sclerosis susceptibility, severity and response to interferon beta treatment by Mahurkar, Sunil, Moldovan, Max, Suppiah, Vijayaprakash, O'Doherty, Catherine

“…Recent genome-wide association studies (GWAS) have successfully identified several gene loci associated with multiple sclerosis (MS) susceptibility, severity…”
Get full text

Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice by Zeppetella, Giovambattista, O'Doherty, Catherine A, Collins, Silke

“…A prospective survey was undertaken to determine the prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease…”
Get full text

Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature by Mahurkar, Sunil, Suppiah, Vijayaprakash, O'Doherty, Catherine

“…Abstract Multiple sclerosis (MS) is one of the most common inflammatory and degenerative autoimmune diseases of the central nervous system with considerable…”
Get full text

Beverage- and brand-specific binge alcohol consumption among underage youth in the US by Naimi, Timothy S., Siegel, Michael, DeJong, William, O'Doherty, Catherine, Jernigan, David

“…Background and objectives: Binge drinking is a common and risky pattern of alcohol consumption among youth; beverage- and brand-specific consumption during…”
Get full text

Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis by O'Doherty, Catherine, Schnabl, Matthew, Spargo, Llewellyn, Cleland, Leslie G, James, Michael, Proudman, Susanna M, Wiese, Michael D

“…Leflunomide is a disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. Not all patients respond to leflunomide and, as it has…”
Get more information

Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients by O'Doherty, Catherine, Favorov, Alexander, Heggarty, Shirley, Graham, Colin, Favorova, Olga, Ochs, Michael, Hawkins, Stanley, Hutchinson, Michael, O'Rourke, Killian, Vandenbroeck, Koen

“…IFN-beta is widely used as first-line immunomodulatory treatment for multiple sclerosis. Response to treatment is variable (30-50% of patients are…”
Get more information

Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine by Wiese, Michael D, Suppiah, Vijayaprakash, O'Doherty, Catherine

“…A number of disease-modifying therapies have become available to treat multiple sclerosis (MS) in recent years. As the effects of these medications are…”
Get more information

Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes by O’Doherty, Catherine, Villoslada, Pablo, Vandenbroeck, Koen

“…Abstract Interferon-β (IFN-β) is routinely prescribed as an immunomodulatory treatment for multiple sclerosis (MS), but is associated with variable clinical…”
Get full text

Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation by Nicholson, Brian D, Jason, Oke, Harris, Dean A, O'Doherty, Catherine, Park, John ES, Virdee, Pradeep, Tonner, Sharon, Vargova, Monika, Engonidou, Lazarina, Riahi, Kaveh, Luan, Ying, Hiom, Sara, Kumar, Harpal, Nandani, Harit, Kurtzman, Kathryn, Yu, Ly-Mee, Freestone, Clare, Pearson, Sarah, Perera, Rafael, Middleton, Mark R.

“…1501 Background: Delays in cancer diagnosis can lead to increased mortality, leading to specialized diagnostic pathways for symptomatic patients when cancer is…”
Get full text

Corrigendum to “Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature” [Autoimmun. Rev. 13 (2013) 178–186] by Mahurkar, Sunil, Suppiah, Vijayaprakash, O'Doherty, Catherine

Get full text

IL7RA Polymorphisms and Susceptibility to Multiple Sclerosis by O'Doherty, Catherine, Kantarci, Orhun, Vandenbroeck, Koen

“…To the Editor: Two independent, well-powered studies have recently identified the interleukin-7 receptor α ( IL7RA ) gene as a susceptibility gene for multiple…”
Get full text

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis by Wiese, Michael D, Rowland, Andrew, Polasek, Thomas M, Sorich, Michael J, O'Doherty, Catherine

“…Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of relapsing forms of multiple sclerosis (MS) in September 2012. Its…”
Get more information

Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours? by Shamash, J, O'Doherty, C A, Oliver, R T, Kelsey, S, Gupta, R K, Gallagher, C J, Newland, A C, Lister, T A

“…Thirty consecutive patients with relapsing germ cell tumours (GCT) were treated with induction chemotherapy and high-dose chemotherapy consolidation (HDCT)…”
Get more information